BRAINSWAY LTD/S (NASDAQ:BWAY) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of BRAINSWAY LTD/S (NASDAQ:BWAY) from a hold rating to a sell rating in a research report report published on Monday morning, Zacks.com reports.

According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “

A number of other analysts also recently commented on the company. LADENBURG THALM/SH SH began coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued a buy rating and a $19.00 target price on the stock. CIBC began coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an outperform rating on the stock. Cantor Fitzgerald began coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an overweight rating and a $17.00 target price on the stock. Raymond James began coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an outperform rating and a $14.00 target price on the stock. Finally, Oppenheimer began coverage on BRAINSWAY LTD/S in a research note on Monday, May 13th. They issued an outperform rating and a $17.00 target price on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. BRAINSWAY LTD/S currently has a consensus rating of Buy and an average target price of $15.80.



Shares of BWAY opened at $10.50 on Monday. BRAINSWAY LTD/S has a 52 week low of $8.00 and a 52 week high of $12.39. The business has a 50-day moving average of $9.94.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BWAY. ARK Investment Management LLC acquired a new position in BRAINSWAY LTD/S in the 2nd quarter worth about $863,000. Delek Group Ltd. acquired a new position in BRAINSWAY LTD/S in the 2nd quarter worth about $3,176,000. Victory Capital Management Inc. acquired a new position in BRAINSWAY LTD/S in the 2nd quarter worth about $157,000. Finally, Noked Capital LTD acquired a new position in BRAINSWAY LTD/S in the 2nd quarter worth about $572,000. 10.84% of the stock is owned by institutional investors.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Recommended Story: How is diluted EPS different from basic EPS?

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BRAINSWAY LTD/S (NASDAQ:BWAY)

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.